tiprankstipranks
Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ:GLUE
US Market
GLUE
Monte Rosa Therapeutics
RESEARCH TOOLSreports

Monte Rosa Therapeutics (GLUE) Income Statement

Compare
380 Followers

Monte Rosa Therapeutics Income Statement

Last quarter (Q4 2025), Monte Rosa Therapeutics's total revenue was $2.78M, a decrease of -95.41% from the same quarter last year. In Q4, Monte Rosa Therapeutics's net income was $-46.13M. See Monte Rosa Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 123.67M$ 75.62M$ 0.00$ 0.00$ 0.00
Gross Profit
$ 115.32M$ 67.50M$ -6.22M$ -8.56M$ 0.00
Operating Expenses
$ 169.52M$ 148.61M$ 137.09M$ 112.38M$ 72.88M
Depreciation and Amortization
$ 8.36M$ 8.12M$ 6.22M$ 3.75M$ 2.13M
EBITDA
$ -45.85M$ -72.99M$ -137.09M$ -108.64M$ -70.75M
Operating Income
$ -54.21M$ -81.11M$ -143.31M$ -112.38M$ -72.88M
Other Income/Expenses
$ 14.48M$ 10.98M$ 8.30M$ 3.88M$ -1.08M
Pretax Income
$ -39.72M$ -70.13M$ -135.01M$ -108.50M$ -73.96M
Net Income
$ -38.63M$ -72.70M$ -135.35M$ -108.50M$ -73.96M
Per Share Metrics
Basic EPS
$ -0.46$ -0.98$ -2.63$ -2.30$ -1.59
Diluted EPS
$ -0.46$ -0.98$ -2.63$ -2.30$ -1.59
Weighted Average Shares Outstanding
 83.07M 73.91M 51.40M 47.23M 46.54M
Weighted Average Shares Outstanding (Diluted)
 83.07M 73.91M 51.40M 47.23M 46.54M
Currency in USD

Monte Rosa Therapeutics Earnings and Revenue History